ApoGen Biotechnologies Overview
- Founded
- 2014

- Status
- Private
- Employees
- 11

- Latest Deal Type
- Series A
- Latest Deal Amount
- $11M

- Investors
- 10
ApoGen Biotechnologies General Information
Description
Developer of a pharmaceutical and biotechnology company intended to focus on the development of a new class of therapeutics targeting drivers of cancer genomic mutation. The company's platform provides therapies that target key drivers of ongoing DNA mutation and tumor evolution, enabling doctors to break drug resistance in cancer treatment.
Contact Information
- 2815 Eastlake Avenue East
- Suite 300
- Seattle, WA 98102
- United States
ApoGen Biotechnologies Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
2. Early Stage VC (Series A) | 23-Aug-2018 | $11M | 0000 | 000.00 | Completed | Generating Revenue |
1. Seed Round | Completed | Startup |
ApoGen Biotechnologies Cap Table
Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
---|---|---|---|---|---|---|---|---|
Series A | 0,000,000 | 00.000000 | 00 | 00 | 00 | 00 | 00.000 |
ApoGen Biotechnologies Comparisons
Industry
00000000
000000 0
PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.
Request a free trialApoGen Biotechnologies Competitors (42)
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Anaeropharma Science | Venture Capital-Backed | Tokyo, Japan | 0 | 000.00 | 0000000000 0 | 000.00 |
000000 00000000000 | Formerly VC-backed | South San Francisco, CA | 000 | 00000 | 000000 - 000 | 00000 |
000000000000 | Venture Capital-Backed | Seattle, WA | 00 | 000.00 | 00000000000 | 000.00 |
0000000 0000000000 | Venture Capital-Backed | Maastricht, Netherlands | 00 | 000.00 | 0000000000 | 000.00 |
000000000 | Venture Capital-Backed | Gaithersburg, MD | 00 | 000.00 | 00000000 | 000.00 |
ApoGen Biotechnologies Executive Team (4)
Name | Title | Board Seat | Contact Info |
---|---|---|---|
Daniel Harki Ph.D | Co-Founder | ||
Reuben Harris Ph.D | Co-Founder | ||
Thong Le | Chief Executive Officer & Board Member | ||
John Santini Jr. | Co-Founder & Board Member |
ApoGen Biotechnologies Board Members (7)
Name | Representing | Role | Since |
---|---|---|---|
Asish Xavier | ApoGen Biotechnologies | Board Member | 000 0000 |
James Sullivan | ApoGen Biotechnologies | Board Member | 000 0000 |
Joel Marcus | ApoGen Biotechnologies | Board Member | 000 0000 |
John Santini Jr. | Self | Co-Founder & Board Member | 000 0000 |
Johnston Erwin | ApoGen Biotechnologies | Board Member | 000 0000 |
ApoGen Biotechnologies Signals
Growth Rate

Growth

Size Multiple


Key Data Points
Twitter Followers
5.5k

Similarweb Unique Visitors
15.0K

Majestic Referring Domains
314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialApoGen Biotechnologies Investors (10)
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|---|---|---|---|---|
AbbVie Ventures | Corporate Venture Capital | Minority | 000 0000 | 000000 0 | |
Accelerator Life Science Partners | Venture Capital | Minority | 000 0000 | 000000 0 | |
Alexandria Venture Investments | Corporate Venture Capital | Minority | 000 0000 | 000000 0 | |
ARCH Venture Partners | Venture Capital | Minority | 000 0000 | 000000 0 | |
Eli Lilly | Corporation | Minority | 000 0000 | 000000 0 |